| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
HDL-targeted therapy is in the spotlight for anti-atherosclerosis treatment. An apoA-I mimetic peptides, FAMP5 has been established, and it confirmed that 16-weeks treatment of FAMP5 inhibits aortic atherosclerotic plaque progressions with an improvement of HDL biological functions in ApoE-/- atherosclerotic model. Furthermore, FAMP5-Duo, a novel symmetrical ApoA-I mimetic peptide which has a lysine with the side chain at the C-terminus end was developed. Consequently, it was identified a gene transferring and confirmed the transferred protein expressions by FAMP5-Duo in addition to an improvement of ABCA1-specificity.
A novel gene transferable HDL-generating peptide was developed and it has significant atheroprotective potential and may prove to be a therapeutic tool for atherosclerotic diseases.
|
